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Summary
 
The human homologue of 
 
Drosophila
 
 Toll (hToll) is a recently cloned receptor of the interleu-
kin 1 receptor (IL-1R) superfamily, and has been implicated in the activation of adaptive im-
munity. Signaling by hToll is shown to occur through sequential recruitment of the adapter
molecule MyD88 and the IL-1R–associated kinase. Tumor necrosis factor receptor–activated
factor 6 (TRAF6) and the nuclear factor 
 
k
 
B (NF-
 
k
 
B)–inducing kinase (NIK) are both in-
volved in subsequent steps of NF-
 
k
 
B activation. Conversely, a dominant negative version of
TRAF6 failed to block hToll-induced activation of stress-activated protein kinase/c-Jun NH
 
2
 
-
terminal kinases, thus suggesting an early divergence of the two pathways.
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k
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I
 
mmune response to infection requires the production of cy-
tokines and costimulatory molecules by antigen-presenting
cells. Distinct cell-associated receptors on myelomonocytic
cells, such as CD14, allow the recognition of pathogen-
associated molecules and trigger natural immune response
by inducing the production of inflammatory cytokines that
subsequently signal to activate adaptive immunity (1).
The molecular mechanisms that control the initial in-
duction of these signals upon infection have been explored
recently. In particular, a novel transmembrane receptor ho-
mologous to the 
 
Drosophila
 
 Toll, human Toll (hToll, also
called TLR4), has been cloned recently (2, 3). The 
 
Drosoph-
ila
 
 Toll protein controls the potent antifungal response in
 
Drosophila
 
 adults (4). Analogously, hToll has been shown to
signal activation of adaptive immunity in humans by induc-
ing the expression of B7.1, IL-6, and IL-8; thus, it repre-
sents a key molecule for the switching from natural to ac-
quired immunity. However, the biochemical transduction
pathway triggered by hToll was ill-defined (2).
hToll is a type I orphan receptor with an extracellular
portion containing leucine-rich repeats, and a cytoplasmic
domain significantly similar to the intracellular portion of
the IL-1R type I (IL-1RI) and the IL-1R accessory protein
(IL-1RAcP) (2, 5, 6); these observations suggest that they
may use an analogous molecular framework for signaling.
IL-1 triggers the activation of distinct transcription fac-
tors, including NF-
 
k
 
B and c-Jun/activator protein 1, that
subsequently drive the transcriptional induction of several
cytokine genes (7). The molecular events occurring from
the IL-1R signaling complex to the induction of NF-
 
k
 
B
activity have been characterized recently; in particular, the
adapter protein MyD88 recruits two distinct putative Ser/
Thr kinases, namely IL-1R–associated kinase (IRAK) and
IRAK-2, to the receptor complex (8–10). IRAK and
IRAK-2 interact subsequently with the adapter molecule
TNFR-activated factor (TRAF) 6, which bridges them to
the protein kinase NF-
 
k
 
B–inducing kinase (NIK) (8, 11,
12). Finally, NIK activates the I-
 
k
 
B kinase complex (in-
cluding IKK
 
a
 
 and IKK
 
b
 
) that directly phosphorylates
I-
 
k
 
B
 
a
 
 (13–17).
In this study, we identified and molecularly ordered the
mediators of the hToll-induced NF-
 
k
 
B and stress-activated
protein kinase (SAPK)/c-Jun NH
 
2
 
-terminal kinase (JNK)
activation cascade.
 
Materials and Methods
 
Expression Vectors and Transfection.
 
TRAF6-Flag, 
 
D
 
TRAF6-
Flag (or TRAF6 298–522), 
 
D
 
TRAF2–Flag (or TRAF2 87–501),
MyD88-AU1, 
 
D
 
MyD88-AU1 (or MyD88 152–296), IRAK,
NIK(KK-AA), and HA-p46SAPK
 
g
 
-pCDNA3 expression vectors
have been described (8, 18). Expression vectors for NH
 
2
 
-terminal
Flag-tagged hToll and 
 
D
 
hToll (amino acids 1–666) were con-
structed by inserting PCR-generated cDNA fragments lacking
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the coding sequence for the signal peptide, into the mammalian
expression vector pFlag-CMV-1 (Eastman Kodak Co., Roches-
ter, NY). CD4/Toll has been described previously (2).
Human embryonic 293 or 293T cells were transiently trans-
fected by the calcium phosphate method with the indicated plas-
mids. The total amount of DNA was kept constant by supple-
mentation with an empty vector (pCDNA3; Invitrogen Corp.,
Carlsbad, CA).
 
Northern Blotting Analysis.
 
Monocytes were separated from
fresh blood of healthy donors as described previously (19). Total
RNA was isolated and analyzed as described previously (19).
 
Coimmunoprecipitation Analysis.
 
24–36 h after transfection,
cells were lysed in 0.5 ml buffer (1% NP-40, 150 mM NaCl, 50
mM Tris, 1 mM EDTA, and protease inhibitor cocktail). Cell ly-
sates were adjusted to 0.7 M NaCl, and the indicated antibodies
were added for 1–4 h at 4
 
8
 
C. Immune complexes were precipi-
tated by the addition of protein G–Sepharose (Sigma Chemical Co.,
St. Louis, MO). After extensive washing (in lysis buffer with the
addition of 0.1% SDS), the Sepharose beads were boiled in sam-
ple buffer, and eluted proteins were fractionated by SDS-PAGE.
Subsequent immunoblotting was performed as described (8).
 
NF-
 
k
 
B Activation Assay.
 
Cells were transfected with endothe-
lial leukocyte adhesion molecule–Luciferase reporter plasmid
(NF-
 
k
 
B luc; 0.1 
 
m
 
g), pCMV-
 
b
 
-galactosidase (
 
b
 
Gal; 0.2 
 
m
 
g), and
the indicated expression vectors. Relative NF-
 
k
 
B activity was
calculated by normalizing relative luciferase activity with 
 
b
 
Gal
activity as described previously (8). Data shown are from one out
of two to five independent experiments with similar qualitative
results. Data from experiments performed in duplicate or tripli-
cate are expressed as mean 
 
6
 
 SE.
 
SAPK/JNK Activation Assay.
 
Cells were transfected with
NF-
 
k
 
B luc (0.5 
 
m
 
g), HA-p46SAPK
 
g
 
-pCDNA3 (2 
 
m
 
g), and the
indicated expression vectors. 48 h after transfection, cells were
lysed in RIPA buffer containing 0.5 mM dithiothreitol, 20 mM
 
b
 
-glycerophosphate, 1 mM sodium orthovanadate, 10 mM so-
dium fluoride, 1 mM PMSF, leupeptin (20 
 
m
 
g/ml), and aprotinin
(20 
 
m
 
g/ml). Lysates were cleared by centrifugation, and protein
concentration was measured using a commercial Bradford protein
assay (Promega Corp., Madison, WI). Equal amounts of each ly-
sate (usually 500 
 
m
 
g) were incubated on ice with 2 
 
m
 
g antiserum
to HA (rabbit polyclonal; Santa Cruz Biotechnology, Inc., Santa
Cruz, CA) for 2 h at 4
 
8
 
C. Immune complexes were collected by
protein A–Sepharose for 20 min and washed four times with
RIPA buffer. Precipitates were boiled in sample buffer and run
onto an SDS-polyacrylamide gel. Finally, immunoblotting was
performed to detect the active phosphorylated form of SAPK
(pThr-183/pTyr-185 of hJNK1), or SAPK as a control, by using
specific antibodies (anti-pJNK mouse monoclonal, and anti-HA;
Figure 1. hToll expression and induction of NF-kB.
(A) Human monocytes were treated with LPS (100 ng/ml)
for different periods of time and analyzed for their hToll
mRNA content by Northern blotting. Two distinct tran-
scripts specific for hToll are detected and induced by LPS
stimulation. (B) Ectopic expression of hToll-Flag and
CD4/Toll but not the mutant version DhToll-Flag activate
NF-kB in 293T cells in a dose-dependent manner, as mea-
sured by NF-kB reporter gene activity. (C) Equal amounts
of hToll-Flag and DhToll-Flag are produced upon ectopic
expression in 293T cells (3.2 mg of each expression con-
struct were used for this experiment). IP, Immunoprecipi-
tation. BLOT, Immunoblotting analysis.
Figure 2. Functional and structural evidence
of MyD88 recruitment to the hToll signaling
complex. (A) Sequence alignment of human
MyD88 (amino acids 152–296), hToll (667–
840), hIL-1RAcP (391–570), and hIL-1RI
(381–569). Alignment was performed with Clust-
all software. Shading, Identical amino acids with
a score ,3. Boxes, Identical amino acids with a
score 5 0. Dots, Conserved amino acids that are
essential for IL-1RI to signal (reference 20). (B)
MyD88 associates with hToll but not with a
truncated version of hToll (DhToll) lacking the
cytoplasmic region sharing sequence similarity
with MyD88. 293T cells were transfected with
hToll-Flag, DhToll-Flag, or IL-1RAcP–Flag as
a positive control together with AU1-tagged
MyD88. The presence of MyD88 that copre-
cipitated with the receptors was detected by
immunoblotting with a rabbit polyclonal antise-
rum to MyD88. (C) DMyD88 inhibits hToll-
induced but not the unrelated TNFR-2–induced
NF-kB activity. 1 mg of receptors and 1.5 mg of
DMyD88 were transfected. Data are expressed
as the percentage of relative receptor-induced
NF-kB activity. 
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Santa Cruz Biotechnology, Inc.). An aliquot of the cell lysate was
also analyzed for NF-
 
k
 
B activation as above.
 
Results and Discussion
 
The expression and eventual regulation of specific tran-
scripts encoding for hToll were analyzed in distinct cell
types that play a critical role in the natural immune re-
sponse. In particular, human monocytes were separated from
healthy donors and treated with the bacterial product LPS
for different periods of time. As shown in Fig. 1 
 
A
 
, specific
transcripts for hToll were present in these cells and were
induced significantly after treatment with LPS. These ob-
servations suggest that modulation of a nonclonal receptor,
namely hToll, after exposure to infectious agents may play
a regulatory role in the natural immune response. Of note,
PMN and dendritic cells also transcribed hToll mRNA at
different levels (our unpublished observations).
We next analyzed the hToll signaling pathway at the mo-
lecular level. A chimeric version of hToll in which the extra
cellular portion was substituted with the corresponding re-
gion of CD4 (CD4/hToll) has been shown previously to in-
duce NF-
 
k
 
B activation in Jurkat cells (2). We engineered
distinct expression constructs encoding for Flag epitope–
tagged hToll (hToll-Flag) or for a truncated version of hToll
that lacks most of the cytoplasmic portion (
 
D
 
hToll-Flag).
Ectopic expression of hToll-Flag but not 
 
D
 
hToll-Flag in-
duced NF-
 
k
 
B activation in human embryonic 293T cells at
levels similar to the CD4/Toll chimeric protein that served
as a positive control (Fig. 1, 
 
B
 
 and 
 
C
 
). From these observa-
tions, it is apparent that either CD4-driven or ectopic ex-
pression–forced aggregation of the cytoplasmic portions of
distinct hToll receptors is sufficient to trigger a signaling cas-
cade that leads ultimately to activation of the transcription
factor NF-
 
k
 
B. Given this, one could speculate that an as yet
unidentified hToll ligand binds to hToll and induces its oli-
gomerization and subsequent signaling cascade, in a manner
similar to IL-1 and TNF with their cognate receptors.
hToll shares significant sequence similarity with distinct
members of the IL-1R family, including IL-1RI, IL-1RAcP,
and MyD88; of note, Phe 513 and Trp 514 in IL-1RI, which
Figure 3. NF-kB activation by hToll occurs through IRAK, TRAF6,
and NIK. (A) IRAK is recruited to hToll but not to the inactive trun-
cated version of hToll (DhToll). IL-1RAcP served as a positive control.
Cells were transfected and analyzed as in Fig. 2 B. (B) IRAK-2 binds very
weakly to hToll. IL-1RI served as a positive control. Cells were trans-
fected and analyzed as in A. (C) DTRAF6 but not the unrelated
DTRAF2 attenuates CD4/Toll-induced NF-kB activity. A dominant
negative mutant version of the downstream molecule NIK [NIK(KK-
AA)] also inhibits CD4/hToll-induced NF-kB activity.
Figure 4. hToll-induced SAPK activation requires MyD88 but not
TRAF6. (A) hToll activates SAPK/JNK in a dose-dependent manner, as
determined by the presence of the active phosphorylated form of JNK
(pJNK). F.I., Fold induction calculated by normalizing pJNK with JNK.
HC, IgG heavy chain. (B) MyD88 (152–296) (DMyD88) but not TRAF6
(289–522) (DTRAF6) abolishes hToll-induced SAPK/JNK phosphoryla-
tion. F.I., Fold induction calculated by normalizing pJNK with JNK.
HC, IgG heavy chain.
Figure 5. Overview of hToll and TNFR-1 signaling pathways. The
diagram shows that the bifurcation of NF-kB and JNK/SAPK activation
by hToll or TNFR-1 occurs at different levels with respect to the specific
TRAFs. TRADD, TNFR-1–associated death domain. RIP, Receptor-
interacting protein.2100 Human Toll Signaling Pathway
are conserved in all of these proteins, have been shown to
be essential for IL-1RI to signal (Fig. 2 A) (20). Since we
have shown recently a homophilic interaction to occur be-
tween the IL-1RAcP and MyD88 throughout their ho-
mologous domains (8), we asked whether hToll and the
adapter protein MyD88 could interact. Upon coexpression,
MyD88 and hToll formed an immunoprecipitable com-
plex; in contrast, a mutant version of hToll, which lacks the
region of homology to MyD88 and which was unable to
induce NF-kB activation, failed to bind MyD88 (Fig. 2 B).
A mutant version of MyD88 (DMyD88), encoding only
for the COOH-terminal IL-1R–like domain, abrogates IL-
1RI/IL-1RAcP–induced NF-kB activation (8); given this,
we analyzed whether DMyD88 could act as a dominant
negative inhibitor of hToll-induced NF-kB activation. As
predicted, DMyD88 specifically inhibited hToll-induced
but not TNFR-2–induced NF-kB activity, lending func-
tional credence to the interaction occurring between hToll
and MyD88 (Fig. 2 C). From these observations, it is ap-
parent that both IL-1R and hToll recruit the adapter pro-
tein MyD88 to their respective signaling complex.
IRAK and IRAK-2 are two additional proximal media-
tors of the IL-1R signaling complex; IRAK is recruited to
the IL-1RAcP, whereas IRAK-2 preferentially binds IL-
1RI (8, 10). Given this, we asked whether IRAK or
IRAK-2 could interact with hToll. Upon ectopic expres-
sion, IRAK and hToll formed an immunoprecipitable
complex. In contrast, IRAK-2 bound only weakly to hToll
compared with IL-1RI (Fig. 3, A and B), thus suggesting
that it may not represent a relevant hToll signal transducer.
NF-kB activation induced by a number of cytokine re-
ceptors is mediated by members of the TRAF adapter fam-
ily. TRAF2, for example, plays a critical role in NF-kB ac-
tivation mediated by TNFR-1 and TNFR-2 (21, 22).
TRAF6 has been implicated in the IL-1 signaling pathway
and has been shown to complex with IRAK and IRAK-2
downstream to the receptor signaling complex (8, 11).
Therefore, we determined whether dominant negative ver-
sions of either could act to inhibit hToll-induced NF-kB
activity. DTRAF6 but not DTRAF2 significantly impaired
hToll-induced NF-kB activity, suggesting that TRAF6
may act as an additional downstream mediator of the
hToll-induced NF-kB activation cascade (Fig. 3 C).
The protein kinase NIK has been shown to act as a gen-
eral mediator of TRAF-induced NF-kB activation (12);
once activated, NIK directly phosphorylates and activates
the IKKa/b complex, which is responsible for I-kBa phos-
phorylation  and subsequent NF-kB activation (13-17).
Dominant negative versions of NIK, in which the critical
lysine has been mutated to alanine [NIK 429–430 (KK-
AA)], act to inhibit NF-kB activation induced by Fas,
TNF, and IL-1 (12). Given this, we asked whether
NIK(KK-AA) could inhibit hToll-induced NF-kB activa-
tion. NIK(KK-AA) abrogated NF-kB activity triggered by
hToll ectopic expression (Fig. 3 C) as well as by TRAF6
overexpression (not shown).
In addition to inducing activation of NF-kB, distinct in-
flammatory cytokines also induce SAPK, also known as
JNK. The active phosphorylated form of SAPK binds to
and phosphorylates the transcription factors c-Jun, activat-
ing transcription factor 2 (ATF2), and ternary complex fac-
tor (TCF)/Elk1 (23–25). In particular, activation of SAPK/
JNK by the TNFR-1 occurs through a TRAF2-dependent
pathway, as a dominant negative version of TRAF2 acts to
inhibit both NF-kB and c-Jun activation induced by TNF
(18, 26, 27). In contrast, a dominant negative version of
NIK, which abrogates TNF-induced NF-kB activation,
fails to inhibit c-Jun phosphorylation, supporting a model
wherein TNF-mediated NF-kB and c-Jun pathways bifur-
cate at TRAF2 (28, 29). Therefore, we analyzed whether
hToll induced SAPK/JNK. Ectopic expression of increas-
ing amounts of hToll-Flag but not DhToll-Flag resulted in
activation of SAPKg as indicated by specific phosphoryla-
tion at Thr 183 and Tyr 185 (Fig. 4 A). Overexpression of
TRAF6 also activated SAPK as described previously (28).
To identify mediators of hToll-mediated JNK activation, we
cotransfected 293 cells with hToll and dominant negative
versions of either MyD88 or TRAF6. Surprisingly,
DMyD88 but not DTRA6 acted to inhibit hToll-triggered
JNK phosphorylation (Fig. 4 B). Importantly, under the
same experimental conditions, both DMyD88 and DTRAF6
abrogated hToll-induced NF-kB activation (96 and 90% in-
hibition, respectively). Additionally, DTRAF6 alone, as well
as DMyD88, failed to activate JNK (data not shown). Col-
lectively, these observations indicate that although ectopic
expression of TRAF6 induced SAPK, a dominant negative
version of TRAF6 failed to inhibit hToll-induced JNK
phosphorylation. Given this, one could speculate that al-
though TRAF6 overexpression is sufficient to activate JNK/
SAPK, endogenous TRAF6 does not provide a significant
contribution to JNK/SAPK activation by hToll (Fig. 5).
Regardless, MyD88 appears to represent the most up-
stream mediator of the hToll-mediated signaling cascade,
which ultimately activates NF-kB and c-Jun, thus driving
transcriptional activation of several cytokines and costimu-
latory molecules. Therefore, it may represent a potentially
useful therapeutic target for controlling the molecular
switch from the innate to the adaptive immune response.
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